Data science is vastly changing the way we do research. Veterinary research is, however, still lagging behind its human counterpart. Why is this the case and can we learn from human health data to close this gap?
Many drugs fail clinical trials, often because preclinical animal models fall short of replicating human physiology. To improve animal welfare, speed up drug development, and reduce costs, we need to rely less on animal models, while also minimizing the number of failures early in the drug development process. Artificial intelligence and machine learning are powerful tools that can help us achieve these goals by predicting a drug’s efficacy, safety, and uptake in preclinical studies. These technologies can help researchers to make informed decisions and optimize testing strategies, improving drug development for both animals and people.
Clinical drug development is a challenging endeavor, but help is at hand! From trial site selection, to patient recruitment, to endpoint characterization – data science integration can help to overcome bottlenecks and improve efficiency in clinical development by generating unique insights to help guide study design and operations. For this strategy to be used to its full potential in Belgium, local partners should optimize data governance and quality, and improve collaboration. This would help the country maintain its status as a leading location for clinical trials.
The application of data science in the early stages of drug development is not new – progress in algorithms and computing power has been ongoing for years. We have reached the point where we have to reflect on the road travelled and look forward to upcoming opportunities and challenges. To further pave the way and reach the top in health data science, stakeholders will have to find each other and work together. Once everyone is on board, data science knows no bounds!
Antwerp, Belgium, 21 June 2022 – Inovigate, a consulting company for the healthcare industry, together with the Belgian Association of Hospital Managers (BAHM), has united
Data science is booming, including in the healthcare sector. However, in order to extract insights and benefits from our health data, we first have to build a solid system for structural data processing and management. To frame the needs for healthcare data reuse in Belgium, Inovigate has united stakeholders and summarized their recommendations in two white papers.
Christine Durinx has been appointed as the new co-Managing Director of the world-class life sciences research institute VIB. Taking over from Jo Bury, Durinx joins VIB’s other co-Managing Director Jérôme Van Biervliet in ushering in a new era of discoveries increasingly driven by data science.
Science for health will connect decisionmakers with researchers, clinicians, and company leaders on the topic of data science in healthcare The event is organized by flanders.bio in collaboration with
Data without science is nothing; just 1s and 0s, floating around a cloud waiting for someone to make sense of them. Data science is the process of extracting value from data, using advanced analytics tools. Enormous amounts of health information are being gathered every second, and we are rapidly getting better at decoding it: turning bytes into insights that can be used to improve the lives of patients. But the pace, methods and ethics of data science adoption varies dramatically between countries and regions. Why should we care about keeping up?
This Summit is designed to create a collaborative environment in which attendees engaged with the speakers, sponsors and other delegates in attendance. The meeting agenda
Ghent, Belgium, 15 January 2025 – ONTOFORCE, a leader in semantic technology for life sciences, headquartered in Ghent, Belgium, and Rancho Biosciences, the leading data science services company headquartered in San Diego, California, have announced a joint collaboration. This partnership aims to transform high quality data-driven research and drug development, providing scientists with unparalleled insights that drive discovery and innovation in the life sciences.
An increasing number of PhD students are concerned about their career prospects. Currently, only around 5-10% of PhD graduates remain in academia — the vast majority have to navigate an unfamiliar job market, where industry demand for their highly educated profiles appears to be in decline. Is a PhD still the best route to professional success? And what can students do to prepare themselves?
In Antwerp, a unique cohort of volunteers is helping to solve one of the world’s most urgent medical challenges: the early detection of cognitive decline. While the study is local, its implications are global — providing the long-term data needed to understand the hidden years of decline in Alzheimer’s disease and other forms of dementia, to enable early diagnosis and intervention.
Belgium puts a lot of resources into research and innovation, supporting the creation of spinouts and startups with brilliant potential health solutions. But as they grow, most of those companies eventually hit a point where local support isn’t enough—they have to look beyond Europe for their manufacturing, clinical trials, and funding needs. How can Belgium close this gap so companies can stay and thrive in Europe?
With the advancements in AI (artificial intelligence) streamlining everything from dentistry to traffic congestion, people in all professions are feeling both excited and uneasy about this increasingly prevalent technology.
